<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154452</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01412</org_study_id>
    <secondary_id>NCI-2011-01412</secondary_id>
    <secondary_id>CDR0000680558</secondary_id>
    <secondary_id>MSKCC-10049</secondary_id>
    <secondary_id>10-049</secondary_id>
    <secondary_id>8406</secondary_id>
    <secondary_id>N01CM62206</secondary_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>U01CA069856</secondary_id>
    <nct_id>NCT01154452</nct_id>
  </id_info>
  <brief_title>Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma</brief_title>
  <official_title>A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase I/II clinical trial is studying the side effects and best dose of
      gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with
      vismodegib and to see how well they work in treating patients with advanced or metastatic
      sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling
      pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch
      signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the maximum-tolerated dose (MTD) of gamma-secretase inhibitor RO4929097
      (RO4929097) when given in combination with fixed-dose Hedgehog antagonist GDC-0449 (GDC-0449)
      which will become the recommended dose for the phase II portion of this study. (Phase Ib) II.
      To assess the progression-free survival (PFS) of the combination of RO4929097 with and
      without GDC-0449 in two arms of patients with advanced sarcoma. (Phase II)

      SECONDARY OBJECTIVES:

      I. To describe the tolerability and adverse event profile of daily GDC-0449 administered
      orally in combination with daily RO4929097 administered orally for 21 consecutive days.
      (Phase Ib) II. To describe the pharmacokinetics of the combination of the combination of
      GDC-0449 and RO4929097. (Phase Ib) III. To assess Response Evaluation Criteria In Solid
      Tumors (RECIST) 1.1 overall response rates (complete and partial response [CR+PR]) for
      combination therapy. (Phase Ib and II) IV. To conduct pharmacodynamic studies in tissue
      biopsies (pre- and post-study) for explorative and hypothesis-generating studies. (Phase Ib
      and II) V. To assess overall survival. (Phase II) VI. To further describe the
      pharmacokinetics and pharmacodynamics of the combination of GDC-0449 and RO4929097 at the
      phase II dose at the continuous schedule. (Phase II) V. To conduct pharmacodynamic studies in
      tissue biopsies (pre- and post- study drug[s]) for explorative and hypothesis generating
      studies. (Phase II)

      OUTLINE: This is a phase I, dose-escalation study of gamma-secretase/notch signalling pathway
      inhibitor RO4929097 followed by a phase II study.

      PHASE IB:

      PART A: Patients receive vismodegib orally (PO) once daily (QD) on days 1-21.

      PART B: Beginning within 7 days of finishing part A, patients receive vismodegib PO and
      gamma-secretase/notch signalling pathway inhibitor RO4929097 PO QD on days 1-21. Courses
      repeat every 21 days in the absence of disease progression or unacceptable toxicity.

      PHASE II: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive gamma-secretase/notch signalling pathway inhibitor RO4929097 PO QD on
      days 1-21.

      ARM II: Patients receive vismodegib PO and gamma-secretase/notch signalling pathway inhibitor
      RO4929097 PO QD on days 1-21.

      In both arms, courses repeat every 21 days in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level Below the MAD, Graded According to NCI-CTCAE Version 4.0 (Phase Ib)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) of the Combination of RO4929097 With and Without GDC-0449 in Patients With Advanced Sarcoma. (Phase II)</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival (PFS) of the combination of RO4929097 with and without GDC-0449 in patients with advanced sarcoma. (Phase II)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (CR + PR) as Assessed by RECIST 1.1 (Phase Ib and II)</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Adult Alveolar Soft Part Sarcoma</condition>
  <condition>Adult Angiosarcoma</condition>
  <condition>Adult Desmoplastic Small Round Cell Tumor</condition>
  <condition>Adult Epithelioid Hemangioendothelioma</condition>
  <condition>Adult Epithelioid Sarcoma</condition>
  <condition>Adult Extraskeletal Myxoid Chondrosarcoma</condition>
  <condition>Adult Extraskeletal Osteosarcoma</condition>
  <condition>Adult Fibrosarcoma</condition>
  <condition>Adult Leiomyosarcoma</condition>
  <condition>Adult Liposarcoma</condition>
  <condition>Adult Malignant Mesenchymoma</condition>
  <condition>Adult Malignant Peripheral Nerve Sheath Tumor</condition>
  <condition>Adult Rhabdomyosarcoma</condition>
  <condition>Adult Synovial Sarcoma</condition>
  <condition>Adult Unclassified Pleomorphic Sarcoma</condition>
  <condition>Chondrosarcoma</condition>
  <condition>Clear Cell Sarcoma of the Kidney</condition>
  <condition>Conjunctival Kaposi Sarcoma</condition>
  <condition>Dermatofibrosarcoma Protuberans</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Metastatic Osteosarcoma</condition>
  <condition>Ovarian Sarcoma</condition>
  <condition>Recurrent Adult Soft Tissue Sarcoma</condition>
  <condition>Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone</condition>
  <condition>Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Kaposi Sarcoma</condition>
  <condition>Recurrent Osteosarcoma</condition>
  <condition>Recurrent Uterine Corpus Sarcoma</condition>
  <condition>Small Intestine Leiomyosarcoma</condition>
  <condition>Stage III Adult Soft Tissue Sarcoma</condition>
  <condition>Stage III Uterine Sarcoma</condition>
  <condition>Stage IV Adult Soft Tissue Sarcoma</condition>
  <condition>Stage IV Uterine Sarcoma</condition>
  <condition>Unclassified Pleomorphic Sarcoma of Bone</condition>
  <arm_group>
    <arm_group_label>Arm I (gamma-secretase inhibitor RO4929097)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (vismodegib and gamma-secretase inhibitor RO4929097)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gamma-Secretase Inhibitor RO4929097</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (gamma-secretase inhibitor RO4929097)</arm_group_label>
    <arm_group_label>Arm II (vismodegib and gamma-secretase inhibitor RO4929097)</arm_group_label>
    <other_name>RO4929097</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (gamma-secretase inhibitor RO4929097)</arm_group_label>
    <arm_group_label>Arm II (vismodegib and gamma-secretase inhibitor RO4929097)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (gamma-secretase inhibitor RO4929097)</arm_group_label>
    <arm_group_label>Arm II (vismodegib and gamma-secretase inhibitor RO4929097)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vismodegib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (vismodegib and gamma-secretase inhibitor RO4929097)</arm_group_label>
    <other_name>Erivedge</other_name>
    <other_name>GDC-0449</other_name>
    <other_name>Hedgehog Antagonist GDC-0449</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed sarcoma

          -  All Patients must have measurable disease as defined by RECIST 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)

          -  There is a minimum of 1 prior therapy; however, there are no minimum systemic therapy
             requirements for well differentiated or de-differentiated liposarcoma, clear cell
             sarcoma, chondrosarcoma, alveolar soft part sarcoma and chordomas which have no
             effective therapies; for Phase Ib, there are no maximum limits to number of prior
             therapies; for Phase II, there is a maximum of 5 prior chemotherapy regimens including
             tyrosine kinase inhibitors (TKI); the last dose of systemic therapy (including TKI)
             must have been given at least 2 weeks prior to initiation of therapy; patients
             receiving nitrosourea (such as BCNU) or mitomycin C must have received their last dose
             of such therapy at least 6 weeks prior to initiation of therapy; patients receiving
             bevacizumab must wait at least 4 weeks; patients receiving experimental immunotherapy
             or antibody based therapies must wait a minimum of 4 weeks or 4 half-lives, whichever
             is longer; this should be discussed with the principal investigator before
             registration; tumor biopsies should be performed only after meeting these
             requirements; patients should recover to less than Common Terminology Criteria for
             Adverse Events (CTCAE) grade 2 toxicities related to previous therapies to be eligible

          -  Patients with metastatic or locally advanced (inoperable) gastrointestinal stromal
             tumor (GIST) must have progressed on imatinib and sunitinib or be intolerant to both
             drugs; the last dose of tyrosine kinase inhibitors imatinib or sunitinib should be
             given at least 2 weeks prior to initiation of therapy

          -  Patients with brain metastasis that have been treated with definitive surgery or
             radiation and have been clinically stable for 3 months following the procedure with no
             neurological signs or symptoms and no requirement for systemic glucocorticoids are
             eligible for study

          -  Patients must not have current evidence of another malignancy except non-melanoma skin
             cancer and superficial bladder cancer

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Hemoglobin &gt;= 9 g/dl

          -  Platelets &gt;= 100,000/mcL

          -  Total bilirubin =&lt; upper limit of normal

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 3 X upper limit of normal

          -  Creatinine =&lt; 1.5 or creatinine clearance &gt;= 60 mL/min/1.73 m^2 for patients with
             creatinine levels above 1.5

          -  Patients treated at Memorial Sloan-Kettering Cancer Center may consent to optional
             tumor biopsies before and after initiation of study drug; tumor biopsies should be
             obtained after fulfilling requirements

          -  Women of child-bearing potential and men must use two forms of contraception (i.e.,
             barrier contraception and one other method of contraception) at least 4 weeks prior to
             study entry, for the duration of study participation, and for at least 12 months
             post-treatment; should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her treating physician immediately;
             women of childbearing potential are required to have a negative pregnancy test (with a
             sensitivity of at least 25 mIU/mL) within 7 days and within 24 hours prior to the
             first dose of GDC-0449 and/or RO4929097 (serum or urine); a pregnancy test (serum or
             urine) will be administered every 3 weeks to all women of childbearing potential, at
             the start of each drug cycle; a positive urine test must be confirmed by a serum
             pregnancy test; prior to dispensing GDC-0449 and/or RO4929097, the investigator must
             confirm and document the patient's use of two contraceptive methods, dates of negative
             pregnancy test, and confirm that patient understands the teratogenic potential of
             GDC-0449 and/or RO4929097

               -  Female patients of childbearing potential are defined as follows:

                    -  Patients with regular menses

                    -  Patients, after menarche with amenorrhea, irregular cycles, or using a
                       contraceptive method that precludes withdrawal bleeding

                    -  Women who have had tubal ligation

               -  Female patients may be considered to NOT be of childbearing potential for the
                  following reasons:

                    -  The patient has undergone total abdominal hysterectomy with bilateral
                       salpingo-oophorectomy or bilateral oophorectomy

                    -  The patient is medically confirmed to be menopausal (no menstrual period)
                       for 24 consecutive months.

                    -  The patient is post-menopausal defined by amenorrhea for at least 1 year in
                       a woman &gt; 45 years old

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients may not receive other investigational agents within 2 weeks of enrollment in
             this study; patients treated with bevacizumab should be off therapy for 4 weeks; other
             experimental or immuno therapies should wait for 4 half-lives or 4 weeks, whichever is
             longer; prior exposure to Notch or Hedgehog inhibitors is not allowed; patients who
             have not recovered to less than CTCAE grade 2 from prior therapies are ineligible

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to GDC-0449 or RO4929097 used in the study

          -  Patients taking medications with narrow therapeutic indices that are metabolized by
             cytochrome P450 (CYP450), including warfarin sodium (CoumadinÂ®) are ineligible;
             patients on warfarin may be considered for enrollment after cessation of warfarin and
             appropriate transition to alternate anti-coagulation agents

          -  Preclinical studies indicate that RO4929097 is a substrate of cytochrome P450, family
             3, subfamily A, polypeptide 4 (CYP3A4) and inducer of CYP3A4 enzyme activity; caution
             should be exercised when dosing RO4929097 concurrently with CYP3A4 substrates,
             inducers, and/or inhibitors; furthermore, patients who are taking concurrent
             medications that are strong inducers/inhibitors or substrates of CYP3A4 should be
             switched to alternative medications to minimize any potential risk; the following
             medications with strong potential for interaction are not allowed: indinavir,
             nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone

          -  Caution should be exercised when dosing GDC-0449 concurrently with medications that
             are substrates of cytochrome P450 family 2, subfamily C, polypeptide 8 (CYP2C8),
             CYP2C9, and CYP2C19 and have narrow therapeutic windows; caution should be exercised
             when dosing GDC-0449 concurrently with inhibitors of CYP3A4

          -  Patients must be able to swallow pills; patients with malabsorption syndrome or other
             condition that would interfere with intestinal absorption

          -  Patients with clinically active liver disease, including active viral or other
             hepatitis or cirrhosis, are ineligible

          -  Patients with uncontrolled electrolyte abnormalities including hypophosphatemia,
             hypocalcemia, hypomagnesemia, hyponatremia or hypokalemia or defined as less than the
             lower limit of normal for the institution, despite adequate electrolyte
             supplementation are excluded from this study

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, a history
             of torsades de pointes or other significant cardiac arrhythmias that require
             antiarrhythmics or other medications known to prolong corrected QT interval (QTc);
             psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with GDC-0449 and/or RO4929097

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible

          -  Cardiovascular: baseline QTc &gt; 450 msec (male) or QTc &gt; 470 msec (female)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mrinal Gounder</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <results_first_submitted>March 18, 2016</results_first_submitted>
  <results_first_submitted_qc>June 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2016</results_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Hemangiosarcoma</mesh_term>
    <mesh_term>Fibrosarcoma</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Sarcoma, Alveolar Soft Part</mesh_term>
    <mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neurofibrosarcoma</mesh_term>
    <mesh_term>Mesenchymoma</mesh_term>
    <mesh_term>Sarcoma, Clear Cell</mesh_term>
    <mesh_term>Dermatofibrosarcoma</mesh_term>
    <mesh_term>Hemangioendothelioma</mesh_term>
    <mesh_term>Hemangioendothelioma, Epithelioid</mesh_term>
    <mesh_term>Histiocytoma, Malignant Fibrous</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RO4929097 10mg</title>
          <description>RO4929097: 10mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="P2">
          <title>RO4929097 15 mg</title>
          <description>RO4929097: 15 mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="P3">
          <title>ARM 1 - RO4929097: 15 mg PO QD</title>
          <description>ARM 1 - RO4929097: 15 mg PO QD</description>
        </group>
        <group group_id="P4">
          <title>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</title>
          <description>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase Ib</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RO4929097 10mg</title>
          <description>RO4929097: 10mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="B2">
          <title>RO4929097 15 mg</title>
          <description>RO4929097: 15 mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="B3">
          <title>ARM 1 - RO4929097: 15 mg PO QD</title>
          <description>ARM 1 - RO4929097: 15 mg PO QD</description>
        </group>
        <group group_id="B4">
          <title>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</title>
          <description>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level Below the MAD, Graded According to NCI-CTCAE Version 4.0 (Phase Ib)</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Phase Ib Participants</title>
            <description>All Phase Ib Participants</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level Below the MAD, Graded According to NCI-CTCAE Version 4.0 (Phase Ib)</title>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) of the Combination of RO4929097 With and Without GDC-0449 in Patients With Advanced Sarcoma. (Phase II)</title>
        <description>Progression-free survival (PFS) of the combination of RO4929097 with and without GDC-0449 in patients with advanced sarcoma. (Phase II)</description>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (CR + PR) as Assessed by RECIST 1.1 (Phase Ib and II)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions</description>
        <time_frame>Up to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RO4929097 10mg</title>
            <description>RO4929097: 10mg PO QD, GDC-0449: 150 mg PO QD</description>
          </group>
          <group group_id="O2">
            <title>RO4929097 15 mg</title>
            <description>RO4929097: 15 mg PO QD, GDC-0449: 150 mg PO QD</description>
          </group>
          <group group_id="O3">
            <title>ARM 1 - RO4929097: 15 mg PO QD</title>
            <description>ARM 1 - RO4929097: 15 mg PO QD</description>
          </group>
          <group group_id="O4">
            <title>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</title>
            <description>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (CR + PR) as Assessed by RECIST 1.1 (Phase Ib and II)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression of Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RO4929097 10mg</title>
          <description>RO4929097: 10mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="E2">
          <title>RO4929097 15 mg</title>
          <description>RO4929097: 15 mg PO QD, GDC-0449: 150 mg PO QD</description>
        </group>
        <group group_id="E3">
          <title>ARM 1 - RO4929097: 15 mg PO QD</title>
          <description>ARM 1 - RO4929097: 15 mg PO QD</description>
        </group>
        <group group_id="E4">
          <title>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</title>
          <description>ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Retroperitoneal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Treatment related secondary malignancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Resp, thoracic &amp; mediastinal disorder Other, spec</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="42" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="56" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E4" events="32" subjects_affected="8" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="12" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="32" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="20" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="34" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E4" events="10" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="18" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="21" subjects_affected="9" subjects_at_risk="35"/>
                <counts group_id="E4" events="16" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="13" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="26" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="50" subjects_affected="14" subjects_at_risk="35"/>
                <counts group_id="E4" events="26" subjects_affected="12" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal &amp; conn tissue disorder Other, spec</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Roche has discontinued further development of the Notch inhibitor (RO4929097) and this Phase II trial was prematurely closed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mrinal Gounder</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4167</phone>
      <email>gounderm@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

